The European Medicines Agency is standing by its original recommendation made earlier this year to suspend a number of medicines that received European Union clearance based on clinical studies conducted by GVK Biosciences in India.
A report by Deutsche Welle says roughly half of the prescription drugs sold online are fake, and Russia is quickly becoming a major source of bogus medications.
Strides Arcolab of India has agreed to buy Aspen Pharmacare's generic pharmaceutical business and related assets in Australia for $287 million.
Singapore, like other Asian countries looking to woo pharmaceutical manufacturers, is moving quickly to meet increasing demand for high-quality water required by strict regulations in the U.S. and European Union.
For the second time in 8 days, law enforcement authorities have charged people with buying drugs illegally and reintroducing them into the legitimate supply chain.
Cipla announced a drug recall of its asthma inhalant levalbuterol from the U.S. market following an FDA warning, and Wockhardt withdrew about a dozen drugs on manufacturing concerns at two of its plants in India.
Hospira is voluntarily recalling 181,704 bags of magnesium sulfate in 5% dextrose injections because labels on the immediate container may have barcodes indicating that it is instead the blood thinner heparin.
Earlier this week, Endo said it would lay out $8 billion for Par Pharmaceuticals to get its hands on that company's sterile injectables biz. Now another deal is brewing in India forClaris Lifesciences operations in that part of the market.
Canadian generics maker Apotex is recalling more than 35,000 bottles of generic Zyprexa, an antipsychotic, that were manufactured at a plant in Toronto that was recently nicked by the FDA for a number of issues.
Illinois-based specialty generics maker Akorn is recalling more than 355,000 bottles of its generic of Bactrim made by one of its recent acquisitions, a company it blamed for some of its financial woes.
A fund for victims of a fungal meningitis outbreak that sprung from contaminated drugs sold by the now-defunct New England Compounding Center has reached $200 million, twice what was initially expected.
Canada's Medicago, a biotech that is using plant technology to manufacture vaccines against Ebola and other viruses, will build a $200 million manufacturing facility in Quebec City. The company is getting substantial support from taxpayers but says when complete, it will more than double its workforce there.
Philadelphia-based generic maker Lannett says it has beefed up its manufacturing, and its generic portfolio, with the acquisition of Silarx for an undisclosed amount.
A joint venture between Malaysia's Pharmaniaga and Saudi Arabia-based Modern Healthcare Solutions to build a pharma plant in Saudi Arabia appears unlikely to make it to the finish line.
In a virtuous cycle, Johnson & Johnson is kicking in some more funding for continous manufacturing research by Rutgers University, whose engineers are helping J&J's Janssen unit transition some products to the new technology at a plant in Puerto Rico.
A Baxter International plant in Spain which has been drafted to help alleviate a shortage of saline in the U.S. has gotten a new FDA designation that gives it more flexibility.
Having laid out plans last fall to expand a biologics plant in the U.S., AstraZeneca is now planning to build a new large-molecule filling facility in Sweden, adding up to 250 jobs in the process. The U.K. drugmaker says the new facility is part of a bigger plan for its biologics manufacturing, the details of which it will announce later.
India's Lupin worked a license deal with Romark Laboratories a couple of years ago to handle sales in the U.S. of liquid diarrhea treatment Alina in the U.S., relying on its reps who handle sales of pediatric drugs. But some recent batches of the drug, often prescribed for children, are not up to specification, and so Romark is recalling them.
India's Wockhardt may have two of its plants banned by the FDA from shipping to the U.S. but it still has product on the market and it says some of it needs to be recalled. The drugmaker is retrieving nearly 95,000 bottles of blood pressure tablets because they are out of spec for thickness.
The combo of Sun Pharmaceutical and Ranbaxy Laboratories just weeks ago created a significant force in the global generics market by any number of measures, which bestows on Sun founder and managing director Dilip Shanghvi new influence in the global pharma industry.